A Phase I Open-Label Study of LNP3794 (BI3011441) in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Latest Information Update: 20 Mar 2023
At a glance
- Drugs LNP 3794 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Lupin
- 16 Mar 2023 Status changed from active, no longer recruiting to completed.
- 20 Jan 2022 New trial record